WHO ICTRP trial
WJOG 14720L
JPRN-jRCTs041210103 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs041210103 |
|---|---|
| Public title | WJOG 14720L |
| Scientific title | Randomized, open label phase II study of brigatinib, carboplatin plus pemetrexed and brigatinib for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer (WJOG14720L) |
| Primary sponsor | Hirotsugu Kenmotsu |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Untreated ALK-rearranged non-squamous non-small cell lung cancer |
| Interventions | The treatment of this study is followed Group A Brigatinib at a dose of 180mg once daily (with a 7-day lead-in period at 90mg) Group B Brigatinib at a dose of 180mg once daily (with a 7-day lead-in period at 90mg) combined with carboplatin… |
| Registration date | Nov 22, 2021 |
| Target size | 110 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: